Financial Ratios Kymera Therapeutics, Inc.
Equities
KYMR
US5015751044
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 87.71 USD | +1.82% |
|
+3.13% | +12.72% |
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
Return on Assets | -11.5 | -16.67 | -17.55 | -20.65 | -15.87 | |||
Return on Total Capital | -16.12 | -20.46 | -20.96 | -22.87 | -16.71 | |||
Return On Equity % | -26.96 | -32.6 | -33.21 | -36.38 | -25.78 | |||
Return on Common Equity | -26.96 | -32.6 | -33.21 | -36.38 | -25.78 | |||
Margin Analysis | ||||||||
Gross Profit Margin % | -88.13 | -250.76 | -140.59 | -410.38 | -707.34 | |||
SG&A Margin | 49.9 | 93.61 | 70.03 | 134.97 | 173.9 | |||
EBITDA Margin % | -135.97 | -340.58 | -207.99 | -532.67 | -864.12 | |||
EBITA Margin % | -138.03 | -344.37 | -210.62 | -545.36 | -881.24 | |||
EBIT Margin % | -138.03 | -344.37 | -210.62 | -545.36 | -881.24 | |||
Income From Continuing Operations Margin % | -137.6 | -330.6 | -186.99 | -475.56 | -794.04 | |||
Net Income Margin % | -137.6 | -330.6 | -186.99 | -475.56 | -794.04 | |||
Net Avail. For Common Margin % | -137.6 | -330.6 | -186.99 | -475.56 | -794.04 | |||
Normalized Net Income Margin | -86 | -206.63 | -116.87 | -290.69 | -490.13 | |||
Levered Free Cash Flow Margin | -80.05 | -192.65 | -124.21 | -269.44 | -346.95 | |||
Unlevered Free Cash Flow Margin | -79.9 | -192.42 | -124.05 | -269.11 | -346.36 | |||
Asset Turnover | ||||||||
Asset Turnover | 0.13 | 0.08 | 0.13 | 0.06 | 0.03 | |||
Fixed Assets Turnover | 3.47 | 2.15 | 1.27 | 0.47 | 0.43 | |||
Receivables Turnover (Average Receivables) | 92.9 | 35.05 | 7.38 | 4.78 | - | |||
Short Term Liquidity | ||||||||
Current Ratio | 4.88 | 5.88 | 4.73 | 7.53 | 10.47 | |||
Quick Ratio | 4.78 | 5.74 | 4.59 | 7.23 | 10.19 | |||
Operating Cash Flow to Current Liabilities | -1.39 | -2.15 | -1.2 | -2.87 | -2.8 | |||
Days Sales Outstanding (Average Receivables) | 3.93 | 10.41 | 49.46 | 76.62 | - | |||
Average Days Payable Outstanding | 11.15 | 9.27 | 11.01 | 9.95 | 5.77 | |||
Long Term Solvency | ||||||||
Total Debt/Equity | 3.91 | 3.54 | 21.44 | 10.5 | 5.21 | |||
Total Debt / Total Capital | 3.76 | 3.42 | 17.65 | 9.5 | 4.95 | |||
LT Debt/Equity | 3.12 | 2.73 | 19.83 | 8.93 | 4.34 | |||
Long-Term Debt / Total Capital | 3.01 | 2.64 | 16.33 | 8.08 | 4.12 | |||
Total Liabilities / Total Assets | 24.14 | 18.73 | 31.4 | 14.56 | 9.36 | |||
EBIT / Interest Expense | -574.46 | -916.23 | -844.54 | -1.03K | -933.9 | |||
EBITDA / Interest Expense | -548.13 | -887.45 | -778.56 | -946.52 | -872.87 | |||
(EBITDA - Capex) / Interest Expense | -557.26 | -903.57 | -954.47 | -998.08 | -876.79 | |||
Total Debt / EBITDA | -0.19 | -0.11 | -0.55 | -0.37 | -0.25 | |||
Net Debt / EBITDA | 5.73 | 3.47 | 2.3 | 3.24 | 4.76 | |||
Total Debt / (EBITDA - Capex) | -0.18 | -0.11 | -0.45 | -0.35 | -0.25 | |||
Net Debt / (EBITDA - Capex) | 5.64 | 3.41 | 1.88 | 3.07 | 4.74 | |||
Growth Over Prior Year | ||||||||
Total Revenues, 1 Yr. Growth % | 114 | -35.71 | 67.84 | -40.11 | -16.7 | |||
Gross Profit, 1 Yr. Growth % | 128.65 | 82.94 | -5.9 | 74.84 | 43.58 | |||
EBITDA, 1 Yr. Growth % | 118.9 | 61.04 | 2.5 | 53.39 | 35.13 | |||
EBITA, 1 Yr. Growth % | 117.11 | 60.41 | 2.65 | 55.08 | 34.6 | |||
EBIT, 1 Yr. Growth % | 117.11 | 60.41 | 2.65 | 55.08 | 34.6 | |||
Earnings From Cont. Operations, 1 Yr. Growth % | 119.81 | 54.47 | -5.07 | 52.32 | 39.08 | |||
Net Income, 1 Yr. Growth % | 119.81 | 54.47 | -5.07 | 52.32 | 39.08 | |||
Normalized Net Income, 1 Yr. Growth % | 119.81 | 54.47 | -5.07 | 48.97 | 40.45 | |||
Diluted EPS Before Extra, 1 Yr. Growth % | -33.69 | 37.45 | -12.28 | 18.47 | 23.53 | |||
Accounts Receivable, 1 Yr. Growth % | -90.58 | 1.78K | 639.53 | -94.95 | - | |||
Net Property, Plant and Equip., 1 Yr. Growth % | 3 | 4.39 | 354.43 | -3.18 | -12.61 | |||
Total Assets, 1 Yr. Growth % | 24.37 | -0.46 | -4.54 | 69.87 | 78.2 | |||
Tangible Book Value, 1 Yr. Growth % | 61.91 | 6.64 | -19.42 | 111.56 | 89.04 | |||
Common Equity, 1 Yr. Growth % | 61.91 | 6.64 | -19.42 | 111.56 | 89.04 | |||
Cash From Operations, 1 Yr. Growth % | -246.31 | 18.72 | -32.83 | 89.16 | 19.74 | |||
Capital Expenditures, 1 Yr. Growth % | -82.44 | 77.58 | 1.12K | -62.77 | -88.71 | |||
Levered Free Cash Flow, 1 Yr. Growth % | -246.63 | 54.74 | 8.21 | 29.93 | 7.26 | |||
Unlevered Free Cash Flow, 1 Yr. Growth % | -246.09 | 54.84 | 8.2 | 29.93 | 7.21 | |||
Compound Annual Growth Rate Over Two Years | ||||||||
Total Revenues, 2 Yr. CAGR % | 398.23 | 17.3 | 3.88 | 0.26 | -29.37 | |||
Gross Profit, 2 Yr. CAGR % | 36.95 | 104.52 | 31.2 | 28.26 | 58.44 | |||
EBITDA, 2 Yr. CAGR % | 53.96 | 87.75 | 28.48 | 25.39 | 43.97 | |||
EBITA, 2 Yr. CAGR % | 54.34 | 86.62 | 28.32 | 26.17 | 44.48 | |||
EBIT, 2 Yr. CAGR % | 54.34 | 86.62 | 28.32 | 26.17 | 44.48 | |||
Earnings From Cont. Operations, 2 Yr. CAGR % | 55.88 | 84.27 | 21.1 | 20.25 | 45.55 | |||
Net Income, 2 Yr. CAGR % | 55.88 | 84.27 | 21.1 | 20.25 | 45.55 | |||
Normalized Net Income, 2 Yr. CAGR % | 55.88 | 84.27 | 21.1 | 18.92 | 44.65 | |||
Diluted EPS Before Extra, 2 Yr. CAGR % | -70.67 | -4.53 | 9.81 | 1.94 | 20.98 | |||
Accounts Receivable, 2 Yr. CAGR % | - | 33.06 | 1.08K | -38.9 | - | |||
Net Property, Plant and Equip., 2 Yr. CAGR % | -1.77 | 3.7 | 117.81 | 109.76 | -8.01 | |||
Total Assets, 2 Yr. CAGR % | 127.86 | 11.27 | -2.52 | 27.34 | 73.98 | |||
Tangible Book Value, 2 Yr. CAGR % | 148.54 | 31.4 | -7.3 | 30.57 | 99.99 | |||
Common Equity, 2 Yr. CAGR % | 148.54 | 31.4 | -7.3 | 30.57 | 99.99 | |||
Cash From Operations, 2 Yr. CAGR % | 168.36 | 31.8 | -10.7 | 12.72 | 50.5 | |||
Capital Expenditures, 2 Yr. CAGR % | 73.26 | -44.16 | 364.66 | 112.76 | -79.5 | |||
Levered Free Cash Flow, 2 Yr. CAGR % | 516.86 | 50.63 | 29.4 | 18.57 | 18.05 | |||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 510.58 | 50.4 | 29.44 | 18.57 | 18.03 | |||
Compound Annual Growth Rate Over Three Years | ||||||||
Total Revenues, 3 Yr. CAGR % | - | 151.77 | 32.18 | -13.54 | -5.74 | |||
Gross Profit, 3 Yr. CAGR % | 53.69 | 50.82 | 57.89 | 44.38 | 33.18 | |||
EBITDA, 3 Yr. CAGR % | 67.05 | 56.28 | 53.45 | 36.29 | 28.56 | |||
EBITA, 3 Yr. CAGR % | 67.35 | 56.33 | 52.9 | 36.68 | 28.92 | |||
EBIT, 3 Yr. CAGR % | 67.35 | 56.33 | 52.9 | 36.68 | 28.92 | |||
Earnings From Cont. Operations, 3 Yr. CAGR % | 67.13 | 55.41 | 47.72 | 30.72 | 26.23 | |||
Net Income, 3 Yr. CAGR % | 67.13 | 55.41 | 47.72 | 30.72 | 26.23 | |||
Normalized Net Income, 3 Yr. CAGR % | 67.13 | 55.41 | 47.72 | 29.75 | 25.7 | |||
Diluted EPS Before Extra, 3 Yr. CAGR % | -51.46 | -50.92 | -7.19 | 12.62 | 8.68 | |||
Accounts Receivable, 3 Yr. CAGR % | - | - | 135.69 | 91.43 | - | |||
Net Property, Plant and Equip., 3 Yr. CAGR % | 111.82 | 0.24 | 69.69 | 66.23 | 56.66 | |||
Total Assets, 3 Yr. CAGR % | 139.27 | 72.89 | 5.73 | 17.3 | 42.43 | |||
Tangible Book Value, 3 Yr. CAGR % | 137.21 | 87.46 | 11.64 | 22.05 | 47.71 | |||
Common Equity, 3 Yr. CAGR % | 137.21 | 87.46 | 11.64 | 22.05 | 47.71 | |||
Cash From Operations, 3 Yr. CAGR % | 93.26 | 104.48 | 5.28 | 14.68 | 15.01 | |||
Capital Expenditures, 3 Yr. CAGR % | 5.6 | 74.69 | 55.92 | 100.32 | -20.06 | |||
Levered Free Cash Flow, 3 Yr. CAGR % | - | 289.04 | 34.9 | 29.57 | 14.68 | |||
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | 286.48 | 34.77 | 29.6 | 14.66 | |||
Compound Annual Growth Rate Over Five Years | ||||||||
Total Revenues, 5 Yr. CAGR % | - | - | - | 74.2 | 2.87 | |||
Gross Profit, 5 Yr. CAGR % | - | - | 44.27 | 41.36 | 58.11 | |||
EBITDA, 5 Yr. CAGR % | - | - | 50.39 | 43.1 | 49.59 | |||
EBITA, 5 Yr. CAGR % | - | - | 50.48 | 43.49 | 49.48 | |||
EBIT, 5 Yr. CAGR % | - | - | 50.48 | 43.49 | 49.48 | |||
Earnings From Cont. Operations, 5 Yr. CAGR % | - | - | 46.92 | 40.25 | 46.85 | |||
Net Income, 5 Yr. CAGR % | - | - | 46.92 | 40.25 | 46.85 | |||
Normalized Net Income, 5 Yr. CAGR % | - | - | 46.92 | 39.63 | 46.48 | |||
Diluted EPS Before Extra, 5 Yr. CAGR % | - | - | -32.71 | -34.25 | 3.19 | |||
Net Property, Plant and Equip., 5 Yr. CAGR % | - | - | 114.19 | 34.68 | 32.83 | |||
Total Assets, 5 Yr. CAGR % | - | - | 67.07 | 52.99 | 29.04 | |||
Tangible Book Value, 5 Yr. CAGR % | - | - | 62.9 | 62.21 | 40.96 | |||
Common Equity, 5 Yr. CAGR % | - | - | 62.9 | 62.21 | 40.96 | |||
Cash From Operations, 5 Yr. CAGR % | - | - | 41.92 | 61.13 | 21.45 | |||
Capital Expenditures, 5 Yr. CAGR % | - | - | 91.01 | 89.02 | -30.75 | |||
Levered Free Cash Flow, 5 Yr. CAGR % | - | - | - | 141.87 | 27.89 | |||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | - | - | 140.92 | 27.8 |
- Stock Market
- Equities
- KYMR Stock
- Financials Kymera Therapeutics, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















